Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5308823 | 0.86 | HTT (0.45) | ALDH1A1HTR2AHTR2CMAPTSMN1; SMN2 | |
| SCHEMBL5314553 | 0.85 | DHPS (0.44) | GRM2KDM4EALDH1A1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL5656624 | 0.84 | DHPS (0.43) | GRM2KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL5654201 | 0.80 | EGLN1 (0.47) | KDM4EALDH1A1MAOBLMNAMAPT | |
| SCHEMBL5654278 | 0.79 | HTR2C (0.41) | HTR2AHTR2CHTR2B | |
| SCHEMBL5314946 | 0.78 | LOXL2 (0.43) | GRM2KDM4EALDH1A1HTR2AHTR2C | |
| SCHEMBL5311904 | 0.77 | MAPT (0.39) | LMNAMAPT | |
| SCHEMBL5314950 | 0.71 | HTR2A (0.44) | GRM2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL5655466 | 0.70 | HTR2A (0.43) | GRM2HTR2AHTR2C | |
| SCHEMBL2611316 | 0.67 | HDAC8 (0.48) | PTGER3MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099912-A1 | Pyrrolo[2,3-F] and [3,2-F]Isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-05-03 | — | — | US | claimed |
| WO-2007053353-A2 | PYRROLO[2,3-F] AND [3,2-F]ISOQUINOLINONE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099912-A1 | Pyrrolo[2,3-F] and [3,2-F]Isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099912-A1 | Pyrrolo[2,3-F] and [3,2-F]Isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands | HTR2C, HTR5A, HTR6 | GRM2 88/4885KDM4E 3935/4885ALDH1A1 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.